Technical Analysis for IOVA - Iovance Biotherapeutics, Inc.

Grade Last Price % Change Price Change
grade C 9.42 0.64% 0.06
IOVA closed up 0.64 percent on Friday, January 18, 2019, on 56 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Flat
See historical IOVA trend table...

Date Alert Name Type % Chg
Jan 18 Narrow Range Bar Range Contraction 0.00%
Jan 18 NR7 Range Contraction 0.00%
Jan 18 NR7-2 Range Contraction 0.00%
Jan 17 50 DMA Support Bullish 0.64%
Jan 17 Narrow Range Bar Range Contraction 0.64%
Jan 17 NR7 Range Contraction 0.64%
Jan 16 Shooting Star Candlestick Bearish 1.18%
Jan 15 Crossed Above 50 DMA Bullish 0.00%
Jan 15 180 Bullish Setup Bullish Swing Setup 0.00%
Jan 14 Fell Below 50 DMA Bearish 4.43%

Older signals for IOVA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
Is IOVA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 19.9
52 Week Low 7.26
Average Volume 1,369,150
200-Day Moving Average 12.57
50-Day Moving Average 9.2308
20-Day Moving Average 9.055
10-Day Moving Average 9.401
Average True Range 0.6528
ADX 11.0
+DI 18.6346
-DI 16.7274
Chandelier Exit (Long, 3 ATRs ) 8.3416
Chandelier Exit (Short, 3 ATRs ) 9.2184
Upper Bollinger Band 10.1724
Lower Bollinger Band 7.9376
Percent B (%b) 0.66
BandWidth 24.680287
MACD Line 0.0382
MACD Signal Line -0.0025
MACD Histogram 0.0407
Fundamentals Value
Market Cap 673.79 Million
Num Shares 71.5 Million
EPS -2.08
Price-to-Earnings (P/E) Ratio -4.53
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.80
Resistance 3 (R3) 9.79 9.67 9.73
Resistance 2 (R2) 9.67 9.57 9.67 9.71
Resistance 1 (R1) 9.54 9.51 9.61 9.55 9.69
Pivot Point 9.42 9.42 9.45 9.42 9.42
Support 1 (S1) 9.29 9.32 9.36 9.30 9.15
Support 2 (S2) 9.17 9.26 9.17 9.13
Support 3 (S3) 9.04 9.17 9.11
Support 4 (S4) 9.05